Market Blog » The Arora Report Stock Market News

CHANGE IN THE LONG SHORT EQUITIES ALLOCATION MODEL

March 25, 2010

With S&P500 June futures at 1176, there is change in our Long Short Equities Model. Please visit Allocation Model page on the site for details. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

THE RESERVE BANK OF INDIA RAISES INTEREST RATES

March 21, 2010

Our Global Multi-Asset Allocation Model has a long allocation to India. The Reserve Bank of India raised its short-term lending and borrowing rates late Friday. It raised the repo rate (rate at which it lends to banks) and reverse repo rate (rate at which banks park their funds with it) by 0.25 per cent each to 5 and 3.75 per cent respectively . This move by theReserve Bank of India does not change the allocation to India in our model. The high priests of Indian markets have almost uniformally called this interest rate increase as surprise. We are not surprised.

TAKE PARTIAL PROFITS ON $STJ (ST. JUDE MEDICAL) RIGHT HERE AT $39.02. TIGHT STOP ON THE REST.

March 19, 2010

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

FDA APPROVES EXPANDED USE OF $BSX (BOSTON SCIENTIFIC) DEVICES

March 18, 2010

Typically we refrain from posting on this blog the information that is easily available elsewhere. In view of us taking long position on BSX immediately after seven broker downgrades and the importance of this FDA decision, we are making an exception. Here is the reason for Boston Scientific going up after hours. Today Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA) has unanimously recommended approval of an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS ® CRT-D. The panel recommended the expansion include the majority of the studied population of the landmark

NOBLE ON $BSX

March 16, 2010

Noble Financial’s checks at Boston Scientific indicate ICD’s and CRT-Ds could return back to the market in 5 days versus some market expectations of months. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

12.5% GAIN ON $BSX (BOSTON SCIENTIFIC) IN THE FACE OF SEVERAL BROKER DOWNGRADES

March 16, 2010

In spite of a negative article in Barron’s Online and two new broker downgrades, we have 12.5% gain at $7.10. This illustrates the power of ZYX Change Method. ZYX Change Method calls for protecting the gains. We scaled in 20% of the full position. Per the trade methodology of ZYX change Method, it is prudent to sell 10% of the full position size or half of the existing $7.10. Tight stops on the rest. www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every

ANATOMY OF $BSX (BOSTON SCIENTIFIC), $MDT (MEDTRONIC) AND $STJ (ST. JUDE MEDICAL) TRADES BASED ON ZYX CHANGE METHOD

March 15, 2010

In ZYX Change Method, every trade must pass through six screens. In the first Change Screen, we are looking for macro changes. In this case, our long time readers know that we have been negative on medical devices industry because we anticipate going forward macro environment will not be conducive to maintaining present margins. The only exception has been $BSX (Boston Scientific) as we have anticipated improving margins. The second screen is Fund Flow Analysis Screen. Here we are using proprietary indicators to dissect money flow. We have been seeing negative Fund Flow Indicators on $MDT (Medtronic) and $STJ (St.